
|Videos|April 29, 2019
JAK Inhibition for the Management of Primary Myelofibrosis
JAK Inhibition for the Management of Primary Myelofibrosis
Advertisement
Case: 66-Year-Old Man Diagnosed With Primary Myelofibrosis
January 2019
- A 66-year old man presents to primary care physician with complaints of fatigue, headache, and abdominal discomfort when taking deep breaths
- PMH: depression
- PE: Splenomegaly ~7 cm below left costal margin
- Lab values:
- HGB: 9.2 g/dL
- Platelets: 242 x 109/L
- WBC: 26.2 x 109/L
- Serum LDH: 1400 U/L
- Serum EPO: 10.9 mU/mL
- Bone Marrow Biopsy:
- MF-3
- Circulating blasts, 1.1%
- JAK V617Fmutation; trisomy 8
- Peripheral Blood Smear: leukoerythroblastosis
- Diagnosis: Primary myelofibrosis
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
4
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
5

































